Bio Pharma Dive

FEBRUARY 23, 2023

Sanofi and its development partner, Sobi, claim the drug’s once-a-week dosing, and its effect on blood-clotting protein levels, will help it compete in the crowded market for hemophilia A treatments.

FDA Approval 281

FDA Approval Drugs Protein Marketing 281

XTalks

FEBRUARY 5, 2025

The approval marks Celltrions seventh biosimilar to be granted marketing authorization in the US and its fifth immunology biologic approval. Avtozma is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist that works by targeting specific inflammatory proteins to dampen immune responses.

FDA Approval 102

FDA Approval Marketing Antibody Immune Response 102

Pharmaceutical Technology

APRIL 13, 2023

Dyadic International has announced expansion of a licence agreement for its C1-cell protein expression platform with South African consortium Rubic One Health. The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa.

Production 279

Production Vaccine Vaccination Protein 279

Pharmaceutical Technology

MAY 30, 2023

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. We are confident it will be the milestone to solidify our position in the global market amid the transition of the pandemic to the endemic phase.”

Vaccine 298

Vaccine Vaccination Protein Medicine 298

XTalks

NOVEMBER 29, 2023

In a significant move towards revolutionizing the alternative dairy protein market, cell programming and biosecurity platform Ginkgo Bioworks has joined forces with Vivici BV , an innovative business-to-business (B2B) ingredients startup. This process ensures optimal protein expression and functionality at a commercial scale.

Protein 105

Protein Production Marketing Development 105

XTalks

JULY 26, 2023

Brevel , an Israeli startup specializing in the conversion of microalgae into alternative proteins, recently secured $18.5 The Tel Aviv-based startup will use the new funding to deliver an alternative protein source that is neutral in taste, highly functional, remarkably sustainable and accessible to the broader food industry.

Protein 97

Protein Production Cosmetics Marketing 97

XTalks

MARCH 26, 2025

In 2025, new initial public offerings (IPOs) are emerging across packaged foods, alternative proteins and tech-enabled food solutions, signaling that scientific investment is becoming a key competitive differentiator. Furthermore, the company reported a Q4 profit of $211 million on $3.95

Packaging 105

Packaging Packaging Protein Production 105

XTalks

JUNE 1, 2023

Univar Solutions , a leading global distributor of ingredients and chemicals, has recently been chosen to distribute ICL’s Rovitaris line of textured plant proteins in North America. The company prides itself on its relentless drive to continually develop and refine products that fill existing gaps in the market.

Protein 98

Protein Production Development Marketing 98

Pharmaceutical Technology

FEBRUARY 25, 2025

Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling strong investor confidence in its cystic fibrosis (CF) pipeline, particularly its lead candidates, SION-719 and SION-451, which work by stabilising the nucleotidebinding domain 1 domain of the CF transmembrane conductance regulator (..)

Marketing 147

Marketing Protein Regulation 147

Bio Pharma Dive

JUNE 16, 2023

The approval of Columvi adds another “bispecific antibody” to the market, highlighting the fast research progress for drugs that target two proteins rather than one.

FDA Approval 180

FDA Approval Drugs Protein Antibody 180

Pharmaceutical Technology

JANUARY 27, 2023

The market for UC is filled with a number of different treatment options, and the pipeline is relatively strong. Some biomarkers, such as c-reactive protein (CRP) and fecal calprotectin (FCP), are used to aid in diagnosis of UC, but there has been no development in this area for use in determining effectiveness of therapies.

Marketing 130

Marketing Protein Development Drugs 130

World of DTC Marketing

DECEMBER 29, 2020

Once introduced into the human body, the protein-making machinery uses this genetic material in our cells to churn out the coronavirus “spike protein,” triggering an immune response. It’s estimated that the COVID 19 vaccine market could be worth almost $100 billion. That’s a hell of an incentive.

Vaccine 307

Vaccine Vaccination Development Clinical Trials 307

Pharmaceutical Technology

MARCH 12, 2024

The US company is part of a burgeoning artificial intelligence (AI) market in early-stage drug development.

Protein 130

Protein Marketing Development Drugs 130

Pharmaceutical Technology

JULY 6, 2022

The European Commission (EC) has granted approval for the expanded conditional marketing authorization (CMA) of Novavax’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), in the European Union (EU) for adolescents of the age 12 to 17 years. A protein-based vaccine, NVX-CoV2373 is made from the genetic sequence of the SARS-CoV-2 virus’ first strain.

Vaccine 264

Vaccine Vaccination Protein Clinical Trials 264

Pharmaceutical Technology

JANUARY 20, 2023

BeiGene has received marketing authorisations for Brukinsa (zanubrutinib) in Great Britain from the Medicines and Healthcare products Regulatory Agency (MHRA) to treat chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL).

Marketing 130

Marketing Bioavailability Trials Clinical Trials 130

XTalks

FEBRUARY 7, 2025

In the biotechnology sector, a biotech IPO occurs when a biotech firm lists its shares on a stock exchange, thereby attracting investment from public markets. The companys approach combines small molecule therapies and targeted protein degradation.

Marketing 66

Marketing Genetics Vaccine Vaccination 66

Pharmaceutical Technology

SEPTEMBER 7, 2022

The diabetic macular oedema (DME) market is anticipated to reach values of $11.1bn in 2031 across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK and Japan).

Marketing 130

Marketing Branding Protein Drugs 130

Pharmaceutical Technology

APRIL 4, 2023

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for AstraZeneca ’s Ultomiris (ravulizumab) to treat neuromyelitis optica spectrum disorder (NMOSD) in adult patients.

Marketing 130

Marketing Clinical Trials Clinical Trials Trials 130

Pharmaceutical Technology

JUNE 29, 2022

Specialty enzymes are proteins that can act as very specific biocatalysts to accelerate reactions and produce the desired target molecule in pharmaceuticals,” explains Kristoffer Laursen, Head of R&D at Novo Nordisk Pharmatech. “In In the evolving biotechnology industry, enzymes are important process aids.

Drugs 295

Drugs Gene Therapy Production Manufacturing 295

Pharmaceutical Technology

DECEMBER 8, 2022

According to the revised deal, Daiichi Sankyo and Kite will transfer the Marketing Authorization for Yescarta to Gilead’s Japan subsidiary, Gilead Sciences K.K., The therapy’s sales and promotion works in Japan following the transfer of marketing authorisation will be carried out by the Kite Cell Therapy Business Unit at Gilead Sciences K.K.

Licensing 305

Licensing Licensing Gene Therapy Gene 305

Pharmaceutical Technology

DECEMBER 15, 2022

The congenital fibrinogen deficiency (CFD) market is expected to grow at a compound annual growth rate (CAGR) of 1.7% through 2031, reaching over $800m across the three major markets (3MM: US, Germany, and Japan), according to GlobalData’s recent report: Congenital Fibrinogen Deficiency: Opportunity Assessment and Forecast.

Marketing 130

Marketing Production Genotype Development 130

Pharmaceutical Technology

MARCH 31, 2023

Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March. Bimervax is a recombinant protein subunit vaccine, marketed by the Girona, Spain-based Hipra.

Vaccine 277

Vaccine Vaccination Immune Response Antibody 277

Pharmaceutical Technology

AUGUST 17, 2022

In the last 20 years, this is the biggest buzz in the vaccine market for Lyme disease,” said Yale School of Medicine associate professor Sukanya Narasimhan, PhD, about the Phase III VLA15 trial. Sanofi had previously developed its own vaccine ImuLyme , which even completed Phase III evaluation, but it did not enter the market.

Vaccine 299

Vaccine Vaccination Bacteria Protein 299

Pharmaceutical Technology

JULY 18, 2022

CFTR modulators work by binding to the defective CFTR protein, improving its function, and in turn reducing the build-up of thick mucus. The post Addressing the treatment gap in the bronchiectasis market appeared first on Pharmaceutical Technology.

Marketing 147

Marketing Trials Development Protein 147

Pharmaceutical Technology

MARCH 16, 2023

These antibodies will be provided to pharma companies for conducting late-stage development and marketing. Immunoprecise Antibodies CEO and president Dr Jennifer Bath said: “As we continue to push the boundaries of cancer therapy, the ability to target intracellular proteins has been the ‘Holy Grail’ in oncology.

Antibody 262

Antibody In-Vivo Pharma Companies Protein 262

XTalks

NOVEMBER 26, 2024

This progressive disease occurs when misfolded transthyretin (TTR) proteins form amyloid deposits in the heart, leading to cardiac dysfunction. A Marketing Authorization Application has been submitted to the European Medicines Agency (EMA), with a decision anticipated in 2025.

Genetic Disease 105

Genetic Disease Genetics Protein Clinical Development 105

Pharmaceutical Technology

JUNE 21, 2023

In the past year, Hemgenix has been granted approval by the US Food and Drug Administration (FDA) and has received conditional marketing authorisation from the European Commission (EC) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This followed positive results from CSL’s Phase III HOPE-B trial (NCT03569891).

Gene Therapy 246

Gene Therapy Gene Protein Sales 246

Pharmaceutical Technology

JANUARY 16, 2024

Disco has built a protein mapping platform for cancer cell surfaces, to unlock targets for the antibody-based therapy market.

Protein 130

Protein Antibody Marketing 130

Pharmaceutical Technology

DECEMBER 23, 2022

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The companies entered the initial agreement in September last year. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Genetics 328

Genetics Medicine Development Gene Therapy 328

XTalks

SEPTEMBER 7, 2023

The Dutch brand, founded by Harmen Treep in 2008, recognized the immense gap in the market and created a line of lactase enzyme supplements tailored to cater to the lactose-intolerant community. The standout feature of Intoleran is its user-friendly lactase drops.

Production 105

Production Marketing Branding Protein 105

Pharma Mirror

OCTOBER 6, 2021

The rising need for early diagnosis of chronic diseases, coupled with growing demand for drugs which work better and have fewer side effects, is largely responsible for the growth of the protein A resin market. Chromatography requires an antibody to bind to a protein A resin.

Research 130

Research Protein Antibody Manufacturing 130

Pharmaceutical Technology

FEBRUARY 10, 2023

However, more highly innovative/high-cost treatments, within infectious disease and neurology space, are likely to enter the market for rare disorders, increasing the number of non-oncology RSAs. Undoubtedly, this has played a factor in the success of market-leading PD-1 inhibitors, Merck & Co.’s

Gene Therapy 263

Gene Therapy Marketing Gene Drugs 263

Pharmaceutical Technology

JULY 29, 2022

An antibody cytokine fusion protein, N-803 is a new interleukin-15 (IL-15) superagonist complex. In January, ImmunityBio and Amyris have concluded a joint venture (JV) agreement announced previously to accelerate the marketing of a Covid-19 vaccine.

Trials 264

Trials Clinical Trials Clinical Trials Licensing 264

Pharmaceutical Technology

SEPTEMBER 2, 2022

Forma focuses on researching, developing and marketing new therapies for patients with sickle cell disease (SCD), rare hematologic diseases and cancers. A group of ailments, haemoglobinopathies is associated with an irregular production or structure of the haemoglobin protein in the red blood cells.

Clinical Trials 264

Clinical Trials Clinical Trials Protein Trials 264

Pharmaceutical Technology

JUNE 15, 2023

The market responded warmly to the reanalysis. Shares in Eloxx were up 19% at market open compared to previous day’s (14 June) close. ELX-02 is a small molecule drug designed to increase the probability full-length proteins are produced by promoting ribosomal function.

Trials 246

Trials Genetics Protein Marketing 246

Pharmaceutical Technology

NOVEMBER 14, 2022

binding antibody, a cell-surface protein which is greatly expressed in ovarian cancer, as well as the maytansinoid payload DM4. In February, the company signed a licencing agreement under which Eli Lilly and Company obtained exclusive rights to conduct the research, development and marketing of ADCs. The ADC comprises an FR?-binding

Antibody 246

Antibody FDA Approval Clinical Trials Clinical Trials 246

Pharmaceutical Technology

JULY 12, 2022

A protein-based vaccine, NVX-CoV2373 is created from the genetic sequence of the SARS-CoV-2 virus’ initial strain. It is formulated with the company’s saponin-based Matrix-M and also comprises a purified protein antigen.

Vaccine 162

Vaccine Vaccination Protein Pharmacy 162